Showing 2683 results
-
Key Release /Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-…
-
Press Release /Results from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will…
-
Press Release /Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)[1]…
-
Press Release /European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable…
-
Key Release /If approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package…
-
Press Release /Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (…
-
Key Release /Basel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)…
-
Press Release /Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion…
-
Press Release /Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line…
-
Press Release /ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna® Findings further support durability and…